Furoscix® (furosemide injection) has been made available for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.

Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for subcutaneous (SC) administration via a wearable, single-use, pre-programmed on-body infusor for outpatient self-administration. The product is supplied as a single-dose 80mg/10mL prefilled cartridge for SC infusion co-packaged with 1 on-body infusor. The on-body infusor delivers 30mg of Furoscix over the first hour followed by 12.5mg per hour for the subsequent 4 hours.

“We are thrilled to announce the commercial availability of Furoscix for patients suffering from worsening heart failure due to congestion,” said John Tucker, Chief Executive Officer of scPharmaceuticals. “By treating these patients with IV-equivalent diuresis, based on similar systemic exposure and diuresis in the comfort of their homes, we believe Furoscix has the potential to reduce avoidable hospital admissions and readmissions and drive significant savings across healthcare systems.”

Continue Reading

Furoscix is intended for use in a setting where the patient can limit their activity for the duration of administration. The treatment is not indicated for emergency situations or in patients with acute pulmonary edema. Furoscix is also not for chronic use and should be replaced with oral diuretics as soon as practical.


  1. scPharmaceuticals announces launch and commercial availability of Furoscix® (furosemide injection). News release. scPharmaceuticals. February 21, 2023. https://www.globenewswire.com/news-release/2023/02/21/2612086/0/en/scPharmaceuticals-Announces-Launch-and-Commercial-Availability-of-FUROSCIX-furosemide-injection.html.
  2. Furoscix. Package insert. scPharmaceuticals Inc.; 2022. Accessed February 21, 2023. https://www.furoscix.com/wp-content/uploads/2022/10/prescribing-information.pdf.

This article originally appeared on MPR